Global Pulmonary Fibrosis Drug Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
LPI (LP Information)' newest research report, the “Pulmonary Fibrosis Drug Industry Forecast” looks at past sales and reviews total world Pulmonary Fibrosis Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Pulmonary Fibrosis Drug sales for 2023 through 2029. With Pulmonary Fibrosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pulmonary Fibrosis Drug industry.
This Insight Report provides a comprehensive analysis of the global Pulmonary Fibrosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Fibrosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pulmonary Fibrosis Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Fibrosis Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Fibrosis Drug.
The global Pulmonary Fibrosis Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Pulmonary Fibrosis Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Pulmonary Fibrosis Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Pulmonary Fibrosis Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Pulmonary Fibrosis Drug players cover Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, MediciNova, Inc., Genentech, Inc., Cipla Inc. and Biogen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Fibrosis Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Pulmonary Fibrosis Drug market?
What factors are driving Pulmonary Fibrosis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pulmonary Fibrosis Drug market opportunities vary by end market size?
How does Pulmonary Fibrosis Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
LPI (LP Information)' newest research report, the “Pulmonary Fibrosis Drug Industry Forecast” looks at past sales and reviews total world Pulmonary Fibrosis Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Pulmonary Fibrosis Drug sales for 2023 through 2029. With Pulmonary Fibrosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pulmonary Fibrosis Drug industry.
This Insight Report provides a comprehensive analysis of the global Pulmonary Fibrosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Fibrosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pulmonary Fibrosis Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Fibrosis Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Fibrosis Drug.
The global Pulmonary Fibrosis Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Pulmonary Fibrosis Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Pulmonary Fibrosis Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Pulmonary Fibrosis Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Pulmonary Fibrosis Drug players cover Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, MediciNova, Inc., Genentech, Inc., Cipla Inc. and Biogen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Fibrosis Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Pirfenidone
- Nintedanib
- Hospital
- Clinic
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Boehringer Ingelheim
- Roche
- FibroGen, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- MediciNova, Inc.
- Genentech, Inc.
- Cipla Inc.
- Biogen
- Galapagos NV
What is the 10-year outlook for the global Pulmonary Fibrosis Drug market?
What factors are driving Pulmonary Fibrosis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pulmonary Fibrosis Drug market opportunities vary by end market size?
How does Pulmonary Fibrosis Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pulmonary Fibrosis Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Pulmonary Fibrosis Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Pulmonary Fibrosis Drug by Country/Region, 2018, 2022 & 2029
2.2 Pulmonary Fibrosis Drug Segment by Type
2.2.1 Pirfenidone
2.2.2 Nintedanib
2.3 Pulmonary Fibrosis Drug Sales by Type
2.3.1 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Pulmonary Fibrosis Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Pulmonary Fibrosis Drug Sale Price by Type (2018-2023)
2.4 Pulmonary Fibrosis Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Pulmonary Fibrosis Drug Sales by Application
2.5.1 Global Pulmonary Fibrosis Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Pulmonary Fibrosis Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Pulmonary Fibrosis Drug Sale Price by Application (2018-2023)
3 GLOBAL PULMONARY FIBROSIS DRUG BY COMPANY
3.1 Global Pulmonary Fibrosis Drug Breakdown Data by Company
3.1.1 Global Pulmonary Fibrosis Drug Annual Sales by Company (2018-2023)
3.1.2 Global Pulmonary Fibrosis Drug Sales Market Share by Company (2018-2023)
3.2 Global Pulmonary Fibrosis Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Pulmonary Fibrosis Drug Revenue by Company (2018-2023)
3.2.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Company (2018-2023)
3.3 Global Pulmonary Fibrosis Drug Sale Price by Company
3.4 Key Manufacturers Pulmonary Fibrosis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pulmonary Fibrosis Drug Product Location Distribution
3.4.2 Players Pulmonary Fibrosis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PULMONARY FIBROSIS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Pulmonary Fibrosis Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Pulmonary Fibrosis Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Pulmonary Fibrosis Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Pulmonary Fibrosis Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Pulmonary Fibrosis Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Pulmonary Fibrosis Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Pulmonary Fibrosis Drug Sales Growth
4.4 APAC Pulmonary Fibrosis Drug Sales Growth
4.5 Europe Pulmonary Fibrosis Drug Sales Growth
4.6 Middle East & Africa Pulmonary Fibrosis Drug Sales Growth
5 AMERICAS
5.1 Americas Pulmonary Fibrosis Drug Sales by Country
5.1.1 Americas Pulmonary Fibrosis Drug Sales by Country (2018-2023)
5.1.2 Americas Pulmonary Fibrosis Drug Revenue by Country (2018-2023)
5.2 Americas Pulmonary Fibrosis Drug Sales by Type
5.3 Americas Pulmonary Fibrosis Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pulmonary Fibrosis Drug Sales by Region
6.1.1 APAC Pulmonary Fibrosis Drug Sales by Region (2018-2023)
6.1.2 APAC Pulmonary Fibrosis Drug Revenue by Region (2018-2023)
6.2 APAC Pulmonary Fibrosis Drug Sales by Type
6.3 APAC Pulmonary Fibrosis Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pulmonary Fibrosis Drug by Country
7.1.1 Europe Pulmonary Fibrosis Drug Sales by Country (2018-2023)
7.1.2 Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2023)
7.2 Europe Pulmonary Fibrosis Drug Sales by Type
7.3 Europe Pulmonary Fibrosis Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pulmonary Fibrosis Drug by Country
8.1.1 Middle East & Africa Pulmonary Fibrosis Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Pulmonary Fibrosis Drug Sales by Type
8.3 Middle East & Africa Pulmonary Fibrosis Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pulmonary Fibrosis Drug
10.3 Manufacturing Process Analysis of Pulmonary Fibrosis Drug
10.4 Industry Chain Structure of Pulmonary Fibrosis Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pulmonary Fibrosis Drug Distributors
11.3 Pulmonary Fibrosis Drug Customer
12 WORLD FORECAST REVIEW FOR PULMONARY FIBROSIS DRUG BY GEOGRAPHIC REGION
12.1 Global Pulmonary Fibrosis Drug Market Size Forecast by Region
12.1.1 Global Pulmonary Fibrosis Drug Forecast by Region (2024-2029)
12.1.2 Global Pulmonary Fibrosis Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Pulmonary Fibrosis Drug Forecast by Type
12.7 Global Pulmonary Fibrosis Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Information
13.1.2 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Boehringer Ingelheim Main Business Overview
13.1.5 Boehringer Ingelheim Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 FibroGen, Inc.
13.3.1 FibroGen, Inc. Company Information
13.3.2 FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 FibroGen, Inc. Main Business Overview
13.3.5 FibroGen, Inc. Latest Developments
13.4 Merck & Co., Inc.
13.4.1 Merck & Co., Inc. Company Information
13.4.2 Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Merck & Co., Inc. Main Business Overview
13.4.5 Merck & Co., Inc. Latest Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Bristol-Myers Squibb Company Company Information
13.5.2 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bristol-Myers Squibb Company Main Business Overview
13.5.5 Bristol-Myers Squibb Company Latest Developments
13.6 MediciNova, Inc.
13.6.1 MediciNova, Inc. Company Information
13.6.2 MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 MediciNova, Inc. Main Business Overview
13.6.5 MediciNova, Inc. Latest Developments
13.7 Genentech, Inc.
13.7.1 Genentech, Inc. Company Information
13.7.2 Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.7.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Genentech, Inc. Main Business Overview
13.7.5 Genentech, Inc. Latest Developments
13.8 Cipla Inc.
13.8.1 Cipla Inc. Company Information
13.8.2 Cipla Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Cipla Inc. Main Business Overview
13.8.5 Cipla Inc. Latest Developments
13.9 Biogen
13.9.1 Biogen Company Information
13.9.2 Biogen Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.9.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Biogen Main Business Overview
13.9.5 Biogen Latest Developments
13.10 Galapagos NV
13.10.1 Galapagos NV Company Information
13.10.2 Galapagos NV Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Galapagos NV Main Business Overview
13.10.5 Galapagos NV Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pulmonary Fibrosis Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Pulmonary Fibrosis Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Pulmonary Fibrosis Drug by Country/Region, 2018, 2022 & 2029
2.2 Pulmonary Fibrosis Drug Segment by Type
2.2.1 Pirfenidone
2.2.2 Nintedanib
2.3 Pulmonary Fibrosis Drug Sales by Type
2.3.1 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Pulmonary Fibrosis Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Pulmonary Fibrosis Drug Sale Price by Type (2018-2023)
2.4 Pulmonary Fibrosis Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Pulmonary Fibrosis Drug Sales by Application
2.5.1 Global Pulmonary Fibrosis Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Pulmonary Fibrosis Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Pulmonary Fibrosis Drug Sale Price by Application (2018-2023)
3 GLOBAL PULMONARY FIBROSIS DRUG BY COMPANY
3.1 Global Pulmonary Fibrosis Drug Breakdown Data by Company
3.1.1 Global Pulmonary Fibrosis Drug Annual Sales by Company (2018-2023)
3.1.2 Global Pulmonary Fibrosis Drug Sales Market Share by Company (2018-2023)
3.2 Global Pulmonary Fibrosis Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Pulmonary Fibrosis Drug Revenue by Company (2018-2023)
3.2.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Company (2018-2023)
3.3 Global Pulmonary Fibrosis Drug Sale Price by Company
3.4 Key Manufacturers Pulmonary Fibrosis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pulmonary Fibrosis Drug Product Location Distribution
3.4.2 Players Pulmonary Fibrosis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PULMONARY FIBROSIS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Pulmonary Fibrosis Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Pulmonary Fibrosis Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Pulmonary Fibrosis Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Pulmonary Fibrosis Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Pulmonary Fibrosis Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Pulmonary Fibrosis Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Pulmonary Fibrosis Drug Sales Growth
4.4 APAC Pulmonary Fibrosis Drug Sales Growth
4.5 Europe Pulmonary Fibrosis Drug Sales Growth
4.6 Middle East & Africa Pulmonary Fibrosis Drug Sales Growth
5 AMERICAS
5.1 Americas Pulmonary Fibrosis Drug Sales by Country
5.1.1 Americas Pulmonary Fibrosis Drug Sales by Country (2018-2023)
5.1.2 Americas Pulmonary Fibrosis Drug Revenue by Country (2018-2023)
5.2 Americas Pulmonary Fibrosis Drug Sales by Type
5.3 Americas Pulmonary Fibrosis Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pulmonary Fibrosis Drug Sales by Region
6.1.1 APAC Pulmonary Fibrosis Drug Sales by Region (2018-2023)
6.1.2 APAC Pulmonary Fibrosis Drug Revenue by Region (2018-2023)
6.2 APAC Pulmonary Fibrosis Drug Sales by Type
6.3 APAC Pulmonary Fibrosis Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pulmonary Fibrosis Drug by Country
7.1.1 Europe Pulmonary Fibrosis Drug Sales by Country (2018-2023)
7.1.2 Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2023)
7.2 Europe Pulmonary Fibrosis Drug Sales by Type
7.3 Europe Pulmonary Fibrosis Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pulmonary Fibrosis Drug by Country
8.1.1 Middle East & Africa Pulmonary Fibrosis Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Pulmonary Fibrosis Drug Sales by Type
8.3 Middle East & Africa Pulmonary Fibrosis Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pulmonary Fibrosis Drug
10.3 Manufacturing Process Analysis of Pulmonary Fibrosis Drug
10.4 Industry Chain Structure of Pulmonary Fibrosis Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pulmonary Fibrosis Drug Distributors
11.3 Pulmonary Fibrosis Drug Customer
12 WORLD FORECAST REVIEW FOR PULMONARY FIBROSIS DRUG BY GEOGRAPHIC REGION
12.1 Global Pulmonary Fibrosis Drug Market Size Forecast by Region
12.1.1 Global Pulmonary Fibrosis Drug Forecast by Region (2024-2029)
12.1.2 Global Pulmonary Fibrosis Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Pulmonary Fibrosis Drug Forecast by Type
12.7 Global Pulmonary Fibrosis Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Information
13.1.2 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Boehringer Ingelheim Main Business Overview
13.1.5 Boehringer Ingelheim Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 FibroGen, Inc.
13.3.1 FibroGen, Inc. Company Information
13.3.2 FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 FibroGen, Inc. Main Business Overview
13.3.5 FibroGen, Inc. Latest Developments
13.4 Merck & Co., Inc.
13.4.1 Merck & Co., Inc. Company Information
13.4.2 Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Merck & Co., Inc. Main Business Overview
13.4.5 Merck & Co., Inc. Latest Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Bristol-Myers Squibb Company Company Information
13.5.2 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bristol-Myers Squibb Company Main Business Overview
13.5.5 Bristol-Myers Squibb Company Latest Developments
13.6 MediciNova, Inc.
13.6.1 MediciNova, Inc. Company Information
13.6.2 MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 MediciNova, Inc. Main Business Overview
13.6.5 MediciNova, Inc. Latest Developments
13.7 Genentech, Inc.
13.7.1 Genentech, Inc. Company Information
13.7.2 Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.7.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Genentech, Inc. Main Business Overview
13.7.5 Genentech, Inc. Latest Developments
13.8 Cipla Inc.
13.8.1 Cipla Inc. Company Information
13.8.2 Cipla Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Cipla Inc. Main Business Overview
13.8.5 Cipla Inc. Latest Developments
13.9 Biogen
13.9.1 Biogen Company Information
13.9.2 Biogen Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.9.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Biogen Main Business Overview
13.9.5 Biogen Latest Developments
13.10 Galapagos NV
13.10.1 Galapagos NV Company Information
13.10.2 Galapagos NV Pulmonary Fibrosis Drug Product Portfolios and Specifications
13.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Galapagos NV Main Business Overview
13.10.5 Galapagos NV Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Pulmonary Fibrosis Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Pulmonary Fibrosis Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Pirfenidone
Table 4. Major Players of Nintedanib
Table 5. Global Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 6. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Table 7. Global Pulmonary Fibrosis Drug Revenue by Type (2018-2023) & ($ million)
Table 8. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2023)
Table 9. Global Pulmonary Fibrosis Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 11. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Table 12. Global Pulmonary Fibrosis Drug Revenue by Application (2018-2023)
Table 13. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2023)
Table 14. Global Pulmonary Fibrosis Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Pulmonary Fibrosis Drug Sales by Company (2018-2023) & (K Units)
Table 16. Global Pulmonary Fibrosis Drug Sales Market Share by Company (2018-2023)
Table 17. Global Pulmonary Fibrosis Drug Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Pulmonary Fibrosis Drug Revenue Market Share by Company (2018-2023)
Table 19. Global Pulmonary Fibrosis Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Pulmonary Fibrosis Drug Producing Area Distribution and Sales Area
Table 21. Players Pulmonary Fibrosis Drug Products Offered
Table 22. Pulmonary Fibrosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Pulmonary Fibrosis Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Pulmonary Fibrosis Drug Sales Market Share Geographic Region (2018-2023)
Table 27. Global Pulmonary Fibrosis Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Pulmonary Fibrosis Drug Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Pulmonary Fibrosis Drug Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Pulmonary Fibrosis Drug Sales Market Share by Country/Region (2018-2023)
Table 31. Global Pulmonary Fibrosis Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Pulmonary Fibrosis Drug Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 34. Americas Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2023)
Table 35. Americas Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2023)
Table 37. Americas Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 38. Americas Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 39. APAC Pulmonary Fibrosis Drug Sales by Region (2018-2023) & (K Units)
Table 40. APAC Pulmonary Fibrosis Drug Sales Market Share by Region (2018-2023)
Table 41. APAC Pulmonary Fibrosis Drug Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Pulmonary Fibrosis Drug Revenue Market Share by Region (2018-2023)
Table 43. APAC Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 44. APAC Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 45. Europe Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 46. Europe Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2023)
Table 47. Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2023)
Table 49. Europe Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 50. Europe Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Pulmonary Fibrosis Drug
Table 58. Key Market Challenges & Risks of Pulmonary Fibrosis Drug
Table 59. Key Industry Trends of Pulmonary Fibrosis Drug
Table 60. Pulmonary Fibrosis Drug Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Pulmonary Fibrosis Drug Distributors List
Table 63. Pulmonary Fibrosis Drug Customer List
Table 64. Global Pulmonary Fibrosis Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Pulmonary Fibrosis Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Pulmonary Fibrosis Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Pulmonary Fibrosis Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Pulmonary Fibrosis Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Pulmonary Fibrosis Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Pulmonary Fibrosis Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Pulmonary Fibrosis Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Pulmonary Fibrosis Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Pulmonary Fibrosis Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Pulmonary Fibrosis Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Pulmonary Fibrosis Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Pulmonary Fibrosis Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Pulmonary Fibrosis Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Boehringer Ingelheim Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 80. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Boehringer Ingelheim Main Business
Table 82. Boehringer Ingelheim Latest Developments
Table 83. Roche Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. Roche Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 85. Roche Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Roche Main Business
Table 87. Roche Latest Developments
Table 88. FibroGen, Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 90. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. FibroGen, Inc. Main Business
Table 92. FibroGen, Inc. Latest Developments
Table 93. Merck & Co., Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 95. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Merck & Co., Inc. Main Business
Table 97. Merck & Co., Inc. Latest Developments
Table 98. Bristol-Myers Squibb Company Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 100. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Bristol-Myers Squibb Company Main Business
Table 102. Bristol-Myers Squibb Company Latest Developments
Table 103. MediciNova, Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 105. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. MediciNova, Inc. Main Business
Table 107. MediciNova, Inc. Latest Developments
Table 108. Genentech, Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 110. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Genentech, Inc. Main Business
Table 112. Genentech, Inc. Latest Developments
Table 113. Cipla Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Cipla Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 115. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Cipla Inc. Main Business
Table 117. Cipla Inc. Latest Developments
Table 118. Biogen Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. Biogen Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 120. Biogen Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Biogen Main Business
Table 122. Biogen Latest Developments
Table 123. Galapagos NV Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. Galapagos NV Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 125. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Galapagos NV Main Business
Table 127. Galapagos NV Latest Developments
Table 1. Pulmonary Fibrosis Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Pulmonary Fibrosis Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Pirfenidone
Table 4. Major Players of Nintedanib
Table 5. Global Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 6. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Table 7. Global Pulmonary Fibrosis Drug Revenue by Type (2018-2023) & ($ million)
Table 8. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2023)
Table 9. Global Pulmonary Fibrosis Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 11. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Table 12. Global Pulmonary Fibrosis Drug Revenue by Application (2018-2023)
Table 13. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2023)
Table 14. Global Pulmonary Fibrosis Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Pulmonary Fibrosis Drug Sales by Company (2018-2023) & (K Units)
Table 16. Global Pulmonary Fibrosis Drug Sales Market Share by Company (2018-2023)
Table 17. Global Pulmonary Fibrosis Drug Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Pulmonary Fibrosis Drug Revenue Market Share by Company (2018-2023)
Table 19. Global Pulmonary Fibrosis Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Pulmonary Fibrosis Drug Producing Area Distribution and Sales Area
Table 21. Players Pulmonary Fibrosis Drug Products Offered
Table 22. Pulmonary Fibrosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Pulmonary Fibrosis Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Pulmonary Fibrosis Drug Sales Market Share Geographic Region (2018-2023)
Table 27. Global Pulmonary Fibrosis Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Pulmonary Fibrosis Drug Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Pulmonary Fibrosis Drug Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Pulmonary Fibrosis Drug Sales Market Share by Country/Region (2018-2023)
Table 31. Global Pulmonary Fibrosis Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Pulmonary Fibrosis Drug Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 34. Americas Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2023)
Table 35. Americas Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2023)
Table 37. Americas Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 38. Americas Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 39. APAC Pulmonary Fibrosis Drug Sales by Region (2018-2023) & (K Units)
Table 40. APAC Pulmonary Fibrosis Drug Sales Market Share by Region (2018-2023)
Table 41. APAC Pulmonary Fibrosis Drug Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Pulmonary Fibrosis Drug Revenue Market Share by Region (2018-2023)
Table 43. APAC Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 44. APAC Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 45. Europe Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 46. Europe Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2023)
Table 47. Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2023)
Table 49. Europe Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 50. Europe Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Pulmonary Fibrosis Drug Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Pulmonary Fibrosis Drug Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Pulmonary Fibrosis Drug Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Pulmonary Fibrosis Drug Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Pulmonary Fibrosis Drug Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Pulmonary Fibrosis Drug
Table 58. Key Market Challenges & Risks of Pulmonary Fibrosis Drug
Table 59. Key Industry Trends of Pulmonary Fibrosis Drug
Table 60. Pulmonary Fibrosis Drug Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Pulmonary Fibrosis Drug Distributors List
Table 63. Pulmonary Fibrosis Drug Customer List
Table 64. Global Pulmonary Fibrosis Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Pulmonary Fibrosis Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Pulmonary Fibrosis Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Pulmonary Fibrosis Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Pulmonary Fibrosis Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Pulmonary Fibrosis Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Pulmonary Fibrosis Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Pulmonary Fibrosis Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Pulmonary Fibrosis Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Pulmonary Fibrosis Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Pulmonary Fibrosis Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Pulmonary Fibrosis Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Pulmonary Fibrosis Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Pulmonary Fibrosis Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Boehringer Ingelheim Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 80. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Boehringer Ingelheim Main Business
Table 82. Boehringer Ingelheim Latest Developments
Table 83. Roche Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. Roche Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 85. Roche Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Roche Main Business
Table 87. Roche Latest Developments
Table 88. FibroGen, Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 90. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. FibroGen, Inc. Main Business
Table 92. FibroGen, Inc. Latest Developments
Table 93. Merck & Co., Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 95. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Merck & Co., Inc. Main Business
Table 97. Merck & Co., Inc. Latest Developments
Table 98. Bristol-Myers Squibb Company Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 100. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Bristol-Myers Squibb Company Main Business
Table 102. Bristol-Myers Squibb Company Latest Developments
Table 103. MediciNova, Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 105. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. MediciNova, Inc. Main Business
Table 107. MediciNova, Inc. Latest Developments
Table 108. Genentech, Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 110. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Genentech, Inc. Main Business
Table 112. Genentech, Inc. Latest Developments
Table 113. Cipla Inc. Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Cipla Inc. Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 115. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Cipla Inc. Main Business
Table 117. Cipla Inc. Latest Developments
Table 118. Biogen Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. Biogen Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 120. Biogen Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Biogen Main Business
Table 122. Biogen Latest Developments
Table 123. Galapagos NV Basic Information, Pulmonary Fibrosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. Galapagos NV Pulmonary Fibrosis Drug Product Portfolios and Specifications
Table 125. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Galapagos NV Main Business
Table 127. Galapagos NV Latest Developments
LIST OF FIGURES
Figure 1. Picture of Pulmonary Fibrosis Drug
Figure 2. Pulmonary Fibrosis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pulmonary Fibrosis Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Pulmonary Fibrosis Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Pulmonary Fibrosis Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Pirfenidone
Figure 10. Product Picture of Nintedanib
Figure 11. Global Pulmonary Fibrosis Drug Sales Market Share by Type in 2022
Figure 12. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2023)
Figure 13. Pulmonary Fibrosis Drug Consumed in Hospital
Figure 14. Global Pulmonary Fibrosis Drug Market: Hospital (2018-2023) & (K Units)
Figure 15. Pulmonary Fibrosis Drug Consumed in Clinic
Figure 16. Global Pulmonary Fibrosis Drug Market: Clinic (2018-2023) & (K Units)
Figure 17. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2022)
Figure 18. Global Pulmonary Fibrosis Drug Revenue Market Share by Application in 2022
Figure 19. Pulmonary Fibrosis Drug Sales Market by Company in 2022 (K Units)
Figure 20. Global Pulmonary Fibrosis Drug Sales Market Share by Company in 2022
Figure 21. Pulmonary Fibrosis Drug Revenue Market by Company in 2022 ($ Million)
Figure 22. Global Pulmonary Fibrosis Drug Revenue Market Share by Company in 2022
Figure 23. Global Pulmonary Fibrosis Drug Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global Pulmonary Fibrosis Drug Revenue Market Share by Geographic Region in 2022
Figure 25. Americas Pulmonary Fibrosis Drug Sales 2018-2023 (K Units)
Figure 26. Americas Pulmonary Fibrosis Drug Revenue 2018-2023 ($ Millions)
Figure 27. APAC Pulmonary Fibrosis Drug Sales 2018-2023 (K Units)
Figure 28. APAC Pulmonary Fibrosis Drug Revenue 2018-2023 ($ Millions)
Figure 29. Europe Pulmonary Fibrosis Drug Sales 2018-2023 (K Units)
Figure 30. Europe Pulmonary Fibrosis Drug Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa Pulmonary Fibrosis Drug Sales 2018-2023 (K Units)
Figure 32. Middle East & Africa Pulmonary Fibrosis Drug Revenue 2018-2023 ($ Millions)
Figure 33. Americas Pulmonary Fibrosis Drug Sales Market Share by Country in 2022
Figure 34. Americas Pulmonary Fibrosis Drug Revenue Market Share by Country in 2022
Figure 35. Americas Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Figure 36. Americas Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Figure 37. United States Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC Pulmonary Fibrosis Drug Sales Market Share by Region in 2022
Figure 42. APAC Pulmonary Fibrosis Drug Revenue Market Share by Regions in 2022
Figure 43. APAC Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Figure 44. APAC Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Figure 45. China Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 49. India Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe Pulmonary Fibrosis Drug Sales Market Share by Country in 2022
Figure 53. Europe Pulmonary Fibrosis Drug Revenue Market Share by Country in 2022
Figure 54. Europe Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Figure 55. Europe Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Figure 56. Germany Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 57. France Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Country in 2022
Figure 62. Middle East & Africa Pulmonary Fibrosis Drug Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Figure 65. Egypt Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Pulmonary Fibrosis Drug in 2022
Figure 71. Manufacturing Process Analysis of Pulmonary Fibrosis Drug
Figure 72. Industry Chain Structure of Pulmonary Fibrosis Drug
Figure 73. Channels of Distribution
Figure 74. Global Pulmonary Fibrosis Drug Sales Market Forecast by Region (2024-2029)
Figure 75. Global Pulmonary Fibrosis Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global Pulmonary Fibrosis Drug Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global Pulmonary Fibrosis Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global Pulmonary Fibrosis Drug Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global Pulmonary Fibrosis Drug Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Pulmonary Fibrosis Drug
Figure 2. Pulmonary Fibrosis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pulmonary Fibrosis Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Pulmonary Fibrosis Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Pulmonary Fibrosis Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Pirfenidone
Figure 10. Product Picture of Nintedanib
Figure 11. Global Pulmonary Fibrosis Drug Sales Market Share by Type in 2022
Figure 12. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2023)
Figure 13. Pulmonary Fibrosis Drug Consumed in Hospital
Figure 14. Global Pulmonary Fibrosis Drug Market: Hospital (2018-2023) & (K Units)
Figure 15. Pulmonary Fibrosis Drug Consumed in Clinic
Figure 16. Global Pulmonary Fibrosis Drug Market: Clinic (2018-2023) & (K Units)
Figure 17. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2022)
Figure 18. Global Pulmonary Fibrosis Drug Revenue Market Share by Application in 2022
Figure 19. Pulmonary Fibrosis Drug Sales Market by Company in 2022 (K Units)
Figure 20. Global Pulmonary Fibrosis Drug Sales Market Share by Company in 2022
Figure 21. Pulmonary Fibrosis Drug Revenue Market by Company in 2022 ($ Million)
Figure 22. Global Pulmonary Fibrosis Drug Revenue Market Share by Company in 2022
Figure 23. Global Pulmonary Fibrosis Drug Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global Pulmonary Fibrosis Drug Revenue Market Share by Geographic Region in 2022
Figure 25. Americas Pulmonary Fibrosis Drug Sales 2018-2023 (K Units)
Figure 26. Americas Pulmonary Fibrosis Drug Revenue 2018-2023 ($ Millions)
Figure 27. APAC Pulmonary Fibrosis Drug Sales 2018-2023 (K Units)
Figure 28. APAC Pulmonary Fibrosis Drug Revenue 2018-2023 ($ Millions)
Figure 29. Europe Pulmonary Fibrosis Drug Sales 2018-2023 (K Units)
Figure 30. Europe Pulmonary Fibrosis Drug Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa Pulmonary Fibrosis Drug Sales 2018-2023 (K Units)
Figure 32. Middle East & Africa Pulmonary Fibrosis Drug Revenue 2018-2023 ($ Millions)
Figure 33. Americas Pulmonary Fibrosis Drug Sales Market Share by Country in 2022
Figure 34. Americas Pulmonary Fibrosis Drug Revenue Market Share by Country in 2022
Figure 35. Americas Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Figure 36. Americas Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Figure 37. United States Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC Pulmonary Fibrosis Drug Sales Market Share by Region in 2022
Figure 42. APAC Pulmonary Fibrosis Drug Revenue Market Share by Regions in 2022
Figure 43. APAC Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Figure 44. APAC Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Figure 45. China Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 49. India Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe Pulmonary Fibrosis Drug Sales Market Share by Country in 2022
Figure 53. Europe Pulmonary Fibrosis Drug Revenue Market Share by Country in 2022
Figure 54. Europe Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Figure 55. Europe Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Figure 56. Germany Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 57. France Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Country in 2022
Figure 62. Middle East & Africa Pulmonary Fibrosis Drug Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2023)
Figure 65. Egypt Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country Pulmonary Fibrosis Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Pulmonary Fibrosis Drug in 2022
Figure 71. Manufacturing Process Analysis of Pulmonary Fibrosis Drug
Figure 72. Industry Chain Structure of Pulmonary Fibrosis Drug
Figure 73. Channels of Distribution
Figure 74. Global Pulmonary Fibrosis Drug Sales Market Forecast by Region (2024-2029)
Figure 75. Global Pulmonary Fibrosis Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global Pulmonary Fibrosis Drug Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global Pulmonary Fibrosis Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global Pulmonary Fibrosis Drug Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global Pulmonary Fibrosis Drug Revenue Market Share Forecast by Application (2024-2029)
